New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
09:02 EDTARWRArrowHead Research to publish data of ARC-520 study
Arrowhead Research announced the publication of data demonstrating multi-log reductions in hepatitis B viral DNA and proteins lasting over 30 days after a single injection in animal models. This suggests that Arrowhead's RNAi-based candidate ARC-520 has the potential to treat chronic hepatitis B virus infection in a fundamentally different manner, with the goal of achieving a functional cure. The paper, entitled "Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection," by Wooddell et al, was published online ahead of print in the journal Molecular Therapy. In the publication, Arrowhead scientists describe the use of a novel Dynamic PolyConjugate technology to deliver small interfering RNAs designed against the hepatitis B virus.
News For ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
11:37 EDTARWROppenheimer reports 5.49% passive stake in Arrowhead
January 23, 2015
08:14 EDTARWRBridger Management reports 5.5% passive stake in Arrowhead
Subscribe for More Information
January 22, 2015
10:03 EDTARWROn the Fly: Analyst Downgrade Summary
Subscribe for More Information
09:16 EDTARWROn The Fly: Pre-market Movers
Subscribe for More Information
07:14 EDTARWRArrowhead downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
06:33 EDTARWRArrowhead downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use